NEW YORK (GenomeWeb News) – Caliper Life Sciences and Korean molecular diagnostics firm Seegene today announced an alliance to enable Seegene's SeePlex multiplex diagnostic assays to run on Caliper's LabChip Dx platform.
The firms will co-market Caliper's LabChip Dx platform and Seegene's complete line of multiplex diagnostic content effective immediately. They also will work together to implement specific content and platform technology development efforts to expand the number of diagnostic tests available.
Seegene's network of distributors will market and distribute the Seeplex assays outside of the US in a preferred partnership for use with the LabChip Dx, the firms added in a joint statement.
The partnership will leverage Seegene's Dual Priming Oligonucleotide approach to PCR-based assays, which uses a new technique for DNA priming that is structurally and functionally different from traditional PCR priming, the firms said.
Among Seegene's DPO assays are multiplex tests for human papillomavirus, respiratory viruses, and vancomycin-resistant Enterococcus.
"We believe that Seegene's DPO technology uniquely enables sensitive and specific, highly multiplexed assays directly from clinical samples, significantly improving the economics of today for centralized and hospital-based diagnostic testing," Caliper President and CEO Kevin Hrusovsky said in a statement.
Caliper launched the LabChip Dx system yesterday with a focus on building its presence in the molecular diagnostics market. The system can analyze large numbers of multiplex samples using minimal sample volume and avoids the need to further purify or dilute diagnostic PCR products, the firm said. The new system also includes specific identification, scoring, and reporting software.